{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:07:34Z","timestamp":1788898054603,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Canine keratoconjunctivitis sicca (KCS) is predominantly an immune-mediated disease. Current therapy of canine KCS is mainly by immunosuppressant, but the effectiveness was limited in some patients. In the past few years, some studies showed the results of the use of mesenchymal stem cells in treating canine KCS via periocular injections. However, the periocular injection procedure requires sedation or general anesthesia, and may lead to iatrogenic or incidental injury during the injection process. The aim of this study was to investigate the efficacy of topical allogenic canine adipose-derived mesenchymal stem cells (cAD-MSCs) in clinical patients of canine KCS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The cAD-MSCs used in this study were characterized for their capability of tri-lineage differentiation and immunomodulatory properties. In addition, preparation methods for eye drops of cAD-MSCs was developed and its optimal preservation was tested. The canine KCS patients were recruited for clinical trial and divided into two groups based on their history of previous treatment. All patients received topical cAD-MSCs treatment once per week for 6 consecutive weeks and complete ophthalmic examinations were performed 1\u2009week before treatment (week 0) and at 3rd, 6th, 9th weeks, respectively. The results showed that the quantity and quality of tears have improved significantly following topical cAD-MSCs treatment based on Schirmers tear test-1 and tear break-up time. More than half of all patients were found improved in the tear quantity. In particular, 56.5% of the patients that were unresponsive to prior immunosuppressant therapy had an effective increase in tear volume. The severity of clinical signs was also ameliorated according to the numeric rating scale score from both patient owners and the clinician.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>To sum up, topical cAD-MSCs may be beneficial especially in KCS patients with poor owner compliance for frequent daily use of eye drops or those who are unresponsive to immunosuppressant therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-022-03303-7","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T05:04:09Z","timestamp":1654837449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Topical applications of allogeneic adipose-derived mesenchymal stem cells ameliorate the canine keratoconjunctivitis sicca"],"prefix":"10.1186","volume":"18","author":[{"given":"Li-Ning","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ho","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Tien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"3303_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.preteyeres.2014.11.001","volume":"45","author":"RJ Braun","year":"2015","unstructured":"Braun RJ, King-Smith PE, Begley CG, Li L, Gewecke NR. Dynamics and function of the tear film in relation to the blink cycle. Prog Retin Eye Res. 2015;45:132\u201364.","journal-title":"Prog Retin Eye Res"},{"key":"3303_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cvsm.2007.12.002","volume":"38","author":"DL Williams","year":"2008","unstructured":"Williams DL. Immunopathogenesis of keratoconjunctivitis sicca in the dog. Vet Clin North Am Small Anim Pract. 2008;38:251\u2013268, vi.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"3303_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4314\/ovj.v8i1.8","volume":"8","author":"DL Williams","year":"2018","unstructured":"Williams DL, Tighe AA. Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. Open Vet J. 2018;8:47\u201352.","journal-title":"Open Vet J"},{"key":"3303_CR4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/archopht.1989.01070020276038","volume":"107","author":"RL Kaswan","year":"1989","unstructured":"Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol. 1989;107:1210\u20136.","journal-title":"Arch Ophthalmol"},{"key":"3303_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0161-6420(95)31071-8","volume":"102","author":"SL Palmer","year":"1995","unstructured":"Palmer SL, Bowen PA 2nd, Green K. Tear flow in cyclosporine recipients. Ophthalmology. 1995;102:118\u201321.","journal-title":"Ophthalmology"},{"key":"3303_CR6","first-page":"653","volume":"42","author":"CP Moore","year":"2001","unstructured":"Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci. 2001;42:653\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3303_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1463-5224.2005.00390.x","volume":"8","author":"A Berdoulay","year":"2005","unstructured":"Berdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol. 2005;8:225\u201332.","journal-title":"Vet Ophthalmol"},{"key":"3303_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1556\/004.2016.030","volume":"64","author":"K Radziejewski","year":"2016","unstructured":"Radziejewski K, Balicki I. Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. Acta Vet Hung. 2016;64:313\u201329.","journal-title":"Acta Vet Hung"},{"key":"3303_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.tvjl.2007.08.034","volume":"179","author":"R Ofri","year":"2009","unstructured":"Ofri R, Lambrou GN, Allgoewer I, Graenitz U, Pena TM, Spiess BM, et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine a. Vet J. 2009;179:70\u20137.","journal-title":"Vet J"},{"key":"3303_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1463-5224.2009.00675.x","volume":"12","author":"RL Swinger","year":"2009","unstructured":"Swinger RL, Schmidt KA Jr, Dubielzig RR. Keratoconjunctivitis associated with toxoplasma gondii in a dog. Vet Ophthalmol. 2009;12:56\u201360.","journal-title":"Vet Ophthalmol"},{"key":"3303_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1463-5224.2010.00858.x","volume":"14","author":"J Dreyfus","year":"2011","unstructured":"Dreyfus J, Schobert CS, Dubielzig RR. Superficial corneal squamous cell carcinoma occurring in dogs with chronic keratitis. Vet Ophthalmol. 2011;14:161\u20138.","journal-title":"Vet Ophthalmol"},{"key":"3303_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315\u20137.","journal-title":"Cytotherapy"},{"key":"3303_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","volume":"14","author":"M Mendicino","year":"2014","unstructured":"Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14:141\u20135.","journal-title":"Cell Stem Cell"},{"key":"3303_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/cdd.2013.158","volume":"21","author":"S Ma","year":"2014","unstructured":"Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21:216\u201325.","journal-title":"Cell Death Differ"},{"key":"3303_CR15","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1016\/j.yexcr.2010.08.008","volume":"316","author":"R Yanez","year":"2010","unstructured":"Yanez R, Oviedo A, Aldea M, Bueren JA, Lamana ML. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res. 2010;316:3109\u201323.","journal-title":"Exp Cell Res"},{"key":"3303_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1182\/blood-2006-02-002246","volume":"109","author":"K Sato","year":"2007","unstructured":"Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007;109:228\u201334.","journal-title":"Blood"},{"key":"3303_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4049\/jimmunol.1302164","volume":"192","author":"C Xu","year":"2014","unstructured":"Xu C, Yu P, Han X, Du L, Gan J, Wang Y, et al. TGF-\u03b2 promotes immune responses in the presence of mesenchymal stem cells. J Immunol. 2014;192:103\u20139.","journal-title":"J Immunol"},{"key":"3303_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/scd.2016.0207","volume":"26","author":"L Chow","year":"2017","unstructured":"Chow L, Johnson V, Coy J, Regan D, Dow S. Mechanisms of immune suppression utilized by canine adipose and bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2017;26:374\u201389.","journal-title":"Stem Cells Dev"},{"key":"3303_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/527926","volume":"2015","author":"AJ Villatoro","year":"2015","unstructured":"Villatoro AJ, Fernandez V, Claros S, Rico-Llanos GA, Becerra J, Andrades JA. Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. Biomed Res Int. 2015;2015:527926.","journal-title":"Biomed Res Int"},{"key":"3303_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3727\/215517916X693366","volume":"8","author":"MK Bittencourt","year":"2016","unstructured":"Bittencourt MK, Barros MA, Martins JF, Vasconcellos JP, Morais BP, Pompeia C, et al. Allogeneic mesenchymal stem cell transplantation in dogs with Keratoconjunctivitis sicca. Cell Med. 2016;8:63\u201377.","journal-title":"Cell Med"},{"key":"3303_CR21","doi-asserted-by":"crossref","unstructured":"Hermida-Prieto M, Garcia-Castro J, Marinas-Pardo L. Systemic Treatment of Immune-Mediated Keratoconjunctivitis Sicca with Allogeneic Stem Cells Improves the Schirmer Tear Test Score in a Canine Spontaneous Model of Disease. J Clin Med. 2021;10:5981.","DOI":"10.3390\/jcm10245981"},{"key":"3303_CR22","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jcyt.2013.06.009","volume":"15","author":"SA Park","year":"2013","unstructured":"Park SA, Reilly CM, Wood JA, Chung DJ, Carrade DD, Deremer SL, et al. Safety and immunomodulatory effects of allogeneic canine adipose-derived mesenchymal stromal cells transplanted into the region of the lacrimal gland, the gland of the third eyelid and the knee joint. Cytotherapy. 2013;15:1498\u2013510.","journal-title":"Cytotherapy"},{"key":"3303_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/250230","volume":"2014","author":"E Beyazyildiz","year":"2014","unstructured":"Beyazyildiz E, Pinarli FA, Beyazyildiz O, Hekimoglu ER, Acar U, Demir MN, et al. Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model. Stem Cells Int. 2014;2014:250230.","journal-title":"Stem Cells Int"},{"key":"3303_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1292\/jvms.14-0265","volume":"77","author":"YP Chang","year":"2015","unstructured":"Chang YP, Hong HP, Lee YH, Liu IH. The canine epiphyseal-derived mesenchymal stem cells are comparable to bone marrow derived-mesenchymal stem cells. J Vet Med Sci. 2015;77:273\u201380.","journal-title":"J Vet Med Sci"},{"key":"3303_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1089\/ten.tea.2007.0207","volume":"14","author":"M Neupane","year":"2008","unstructured":"Neupane M, Chang C-C, Kiupel M, Yuzbasiyan-Gurkan V. Isolation and characterization of canine adipose\u2013derived mesenchymal stem cells. Tissue Eng Part A. 2008;14:1007\u201315.","journal-title":"Tissue Eng Part A"},{"key":"3303_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/stem.1118","volume":"30","author":"L von Bahr","year":"2012","unstructured":"von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30:1575\u20138.","journal-title":"Stem Cells"},{"key":"3303_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fbioe.2019.00009","volume":"7","author":"P Mancuso","year":"2019","unstructured":"Mancuso P, Raman S, Glynn A, Barry F, Murphy JM. Mesenchymal stem cell therapy for osteoarthritis: the critical role of the cell Secretome. Front Bioeng Biotechnol. 2019;7:9.","journal-title":"Front Bioeng Biotechnol"},{"key":"3303_CR28","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1038\/s41598-018-24971-2","volume":"8","author":"M Li","year":"2018","unstructured":"Li M, Khong D, Chin LY, Singleton A, Parekkadan B. Therapeutic delivery specifications identified through compartmental analysis of a mesenchymal stromal cell-immune reaction. Sci Rep. 2018;8:6816.","journal-title":"Sci Rep"},{"key":"3303_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13287-020-01947-6","volume":"11","author":"T Nicotra","year":"2020","unstructured":"Nicotra T, Desnos A, Halimi J, Antonot H, Reppel L, Belmas T, et al. Mesenchymal stem\/stromal cell quality control: validation of mixed lymphocyte reaction assay using flow cytometry according to ICH Q2(R1). Stem Cell Res Ther. 2020;11:426.","journal-title":"Stem Cell Res Ther"},{"key":"3303_CR30","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1007\/s00253-018-8912-x","volume":"102","author":"V Jossen","year":"2018","unstructured":"Jossen V, van den Bos C, Eibl R, Eibl D. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Appl Microbiol Biotechnol. 2018;102:3981\u201394.","journal-title":"Appl Microbiol Biotechnol"},{"key":"3303_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.5966\/sctm.2014-0199","volume":"4","author":"YB Cho","year":"2015","unstructured":"Cho YB, Park KJ, Yoon SN, Song KH, Kim DS, Jung SH, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn's fistula. Stem Cells Transl Med. 2015;4:532\u20137.","journal-title":"Stem Cells Transl Med"},{"key":"3303_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/jop.2011.0166","volume":"28","author":"JA Wood","year":"2012","unstructured":"Wood JA, Chung DJ, Park SA, Zwingenberger AL, Reilly CM, Ly I, et al. Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells: an in vivo imaging and migration study. J Ocul Pharmacol Ther. 2012;28:307\u201317.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3303_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0195-5616(90)50052-2","volume":"20","author":"RL Kaswan","year":"1990","unstructured":"Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Vet Clin North Am Small Anim Pract. 1990;20:583\u2013613.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"3303_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1089\/jop.2021.0033","volume":"37","author":"SA Park","year":"2021","unstructured":"Park SA, Good KL, Thomasy SM, Kass PH, Murphy CJ. Effect of withdrawing chronic topical immune modulating treatment on Schirmer tear test values in dogs with dry eye disease: relevance to dry eye studies. J Ocul Pharmacol Ther. 2021;37:394\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3303_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1463-5224.2011.00972.x","volume":"15","author":"M Rhodes","year":"2012","unstructured":"Rhodes M, Heinrich C, Featherstone H, Braus B, Manning S, Cripps PJ, et al. Parotid duct transposition in dogs: a retrospective review of 92 eyes from 1999 to 2009. Vet Ophthalmol. 2012;15:213\u201322.","journal-title":"Vet Ophthalmol"},{"key":"3303_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2019.101525","volume":"39","author":"MR Sgrignoli","year":"2019","unstructured":"Sgrignoli MR, Silva DA, Nascimento FF, Sgrignoli DAM, Nai GA, da Silva MG, et al. Reduction in the inflammatory markers CD4, IL-1, IL-6 and TNFalpha in dogs with keratoconjunctivitis sicca treated topically with mesenchymal stem cells. Stem Cell Res. 2019;39:101525.","journal-title":"Stem Cell Res"},{"key":"3303_CR37","unstructured":"Safarini OA, Keshavamurthy C, Patel P. Calcineurin Inhibitors. [Updated 2022 Feb 12]. In: StatPearls [Internet].\u00a0Treasure Island (FL): StatPearls Publishing; 2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558995\/."},{"key":"3303_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3389\/fimmu.2019.00694","volume":"10","author":"KM van Megen","year":"2019","unstructured":"van Megen KM, van\u2019t Wout ET, Lages Motta J, Dekker B, Nikolic T, Roep BO. Activated mesenchymal stromal cells process and present antigens regulating adaptive immunity. Front Immunol. 2019;10:694.","journal-title":"Front Immunol"},{"key":"3303_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1207\/s15327604jaws0902_3","volume":"9","author":"LA DeLuca","year":"2006","unstructured":"DeLuca LA, Glass SG, Johnson RE, Burger M. Description and evaluation of a canine volunteer blood donor program. J Appl Anim Welf Sci. 2006;9:129\u201341.","journal-title":"J Appl Anim Welf Sci"},{"key":"3303_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12917-017-1053-0","volume":"13","author":"F Bahamondes","year":"2017","unstructured":"Bahamondes F, Flores E, Cattaneo G, Bruna F, Conget P. Omental adipose tissue is a more suitable source of canine mesenchymal stem cells. BMC Vet Res. 2017;13:166.","journal-title":"BMC Vet Res"},{"key":"3303_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3727\/096368909X481764","volume":"19","author":"NM Vieira","year":"2010","unstructured":"Vieira NM, Brandalise V, Zucconi E, Secco M, Strauss BE, Zatz M. Isolation, characterization, and differentiation potential of canine adipose-derived stem cells. Cell Transplant. 2010;19:279\u201389.","journal-title":"Cell Transplant"},{"key":"3303_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1042\/CBI20110304","volume":"36","author":"A Guercio","year":"2012","unstructured":"Guercio A, Di Marco P, Casella S, Cannella V, Russotto L, Purpari G, et al. Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints. Cell Biol Int. 2012;36:189\u201394.","journal-title":"Cell Biol Int"},{"key":"3303_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167442","volume":"11","author":"KA Russell","year":"2016","unstructured":"Russell KA, Chow NH, Dukoff D, Gibson TW, LaMarre J, Betts DH, et al. Characterization and immunomodulatory effects of canine adipose tissue- and bone marrow-derived mesenchymal stromal cells. PLoS One. 2016;11:e0167442.","journal-title":"PLoS One"},{"key":"3303_CR44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2141.2005.05409.x","volume":"129","author":"B Puissant","year":"2005","unstructured":"Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol. 2005;129:118\u201329.","journal-title":"Br J Haematol"},{"key":"3303_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5051\/jpis.2010.40.6.265","volume":"40","author":"HS Kim","year":"2010","unstructured":"Kim HS, Kim KH, Kim SH, Kim YS, Koo KT, Kim TI, et al. Immunomodulatory effect of canine periodontal ligament stem cells on allogenic and xenogenic peripheral blood mononuclear cells. J Periodontal Implant Sci. 2010;40:265\u201370.","journal-title":"J Periodontal Implant Sci"},{"key":"3303_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/scrt223","volume":"4","author":"K-J Lin","year":"2013","unstructured":"Lin K-J, Loi M-X, Lien G-S, Cheng C-F, Pao H-Y, Chang Y-C, et al. Topical administration of orbital fat-derived stem cells promotes corneal tissue regeneration. Stem Cell Res Ther. 2013;4:72.","journal-title":"Stem Cell Res Ther"},{"key":"3303_CR47","first-page":"368","volume":"166","author":"KN Gelatt","year":"1975","unstructured":"Gelatt KN, Peiffer RL Jr, Erickson JL, Gum GG. Evaluation of tear formation in the dog, using a modification of the Schirmer tear test. J Am Vet Med Assoc. 1975;166:368\u201370.","journal-title":"J Am Vet Med Assoc"},{"key":"3303_CR48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1477-7525-10-80","volume":"10","author":"J Khadka","year":"2012","unstructured":"Khadka J, Gothwal VK, McAlinden C, Lamoureux EL, Pesudovs K. The importance of rating scales in measuring patient-reported outcomes. Health Qual Life Outcomes. 2012;10:80.","journal-title":"Health Qual Life Outcomes"},{"key":"3303_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/vop.12462","volume":"20","author":"HE Visser","year":"2017","unstructured":"Visser HE, Tofflemire KL, Love-Myers KR, Allbaugh RA, Ellinwood NM, Dees DD, et al. Schirmer tear test I in dogs: results comparing placement in the ventral vs. dorsal conjunctival fornix. Vet Ophthalmol. 2017;20:522\u20135.","journal-title":"Vet Ophthalmol"},{"key":"3303_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1444-0938.2012.00801.x","volume":"96","author":"XE Wei","year":"2013","unstructured":"Wei XE, Markoulli M, Zhao Z, Willcox MD. Tear film break-up time in rabbits. Clin Exp Optom. 2013;96:70\u20135.","journal-title":"Clin Exp Optom"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-022-03303-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T06:08:32Z","timestamp":1654841312000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-022-03303-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3303"],"URL":"https:\/\/doi.org\/10.1186\/s12917-022-03303-7","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"25 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures in this study were reviewed and approved by National Taiwan University Veterinary Hospital (Clinical Research No: 000030 and 000031) and the Institutional Animal Care and Use Committee of National Taiwan University (IACUC No: NTU106-EL-00097). All methods were performed in accordance with the relevant guidelines and regulations. All donor and patient owners were fully consented about this study and informed consent was obtained from dog owners. This study is reported in accordance with ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A patent application has been filed by the authors Drs. CT Lin and IH Liu relating to the content of the manuscript. The other authors (LNW, CHW) declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}